Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Stéphane Bancel
Person

Stéphane Bancel

Tracked across 8 events · 919 articles · First seen May 29, 2025 · Last active Aug 20, 2026

Sentiment
42
Attention
8
Events
8
Relationships
8
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (8)
6 60
Regulatory
Food and Drug Administration Reverses Moderna Flu Vaccine
Impact: Stéphane Bancel, CEO of Moderna, expressed appreciation for the United States — Food and Drug Administration's engagement and agreement to review the vaccine, highlighting the company's goal to make the flu vaccine available to seniors.
Feb 18, 2026 · 9 articles
7 60
International
DRC Ebola Outbreak Spreads, Hindered by Conflict
Impact: Stéphane Bancel, CEO of Moderna, pledged urgency and scientific rigor in developing a Bundibugyo vaccine.
May 21, 2026 · 627 articles
7 70
Regulatory
FDA Approves Moderna's First mRNA Flu Vaccine
On August 5, 2026, the U.S. United States — Food and Drug Administration (FDA) approved Moderna's mFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine, for adults aged 50 and older. The approval covers traditional approval…
Impact: As CEO, Bancel championed the vaccine and highlighted its importance for seniors and the company's future.
Aug 05, 2026 · 105 articles
8 80
Tech
Moderna Merck mRNA melanoma vaccine trial success
Moderna and Merck & Co. announced on August 19, 2026, that their personalized mRNA cancer vaccine, Intismeran, combined with Merck's immunotherapy drug Pembrolizumab, met its primary and secondary goals in a Phase 3 trial for…
Impact: As CEO of Moderna, Bancel announced the results and highlighted the milestone. His leadership is central to the company's strategic direction and investor confidence.
Aug 19, 2026 · 102 articles
6 60
Tech
CEPI Funds Ebola Bundibugyo Vaccine Development
Impact: Stéphane Bancel>>>, CEO of Moderna>>>, expressed pride in the expanded collaboration, highlighting Moderna's>>> commitment to rapid response to infectious disease threats.
May 22, 2026 · 36 articles
4 0
Regulatory
FDA Rejects Moderna mRNA Flu Vaccine
Impact: Stéphane Bancel, Moderna's CEO, expressed disappointment with the United States — Food and Drug Administration's decision, stating it does not further shared goals of innovation.
Feb 10, 2026 · 6 articles
2 0
Business
Moderna appoints Michael McDonnell to board
Impact: CEO Stéphane Bancel expressed delight at McDonnell's appointment, citing his industry understanding.
Jul 08, 2026 · 6 articles
7 10
Regulatory
FDA Panel Recommends Moderna mRNA Flu Vaccine
Impact: Stéphane Bancel, CEO of Moderna, expressed appreciation for the VRBPAC's review and highlighted the potential of mRNA-1010 to offer a new option for seasonal flu prevention, reinforcing the company's commitment to the vaccine.
Jun 18, 2026 · 28 articles
Key Actions (1)
60 Stéphane Bancel called findings pivotalModerna Merck mRNA...
Relationships (8)
Dean Y. Li ↔ Stéphane Bancel
Dean Y. Li ↔ Stéphane Bancel
Moderna ↔ Stéphane Bancel
Moderna ↔ Stéphane Bancel
Merck Group ↔ Stéphane Bancel
Merck Group ↔ Stéphane Bancel
United States — Centers for Disease Control and Prevention ↔ Stéphane Bancel
United States — Centers for Disease Control and Prevention ↔ Stéphane Bancel
ERGEN INTELLIGENCE
Track Stéphane Bancel live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.